Nestlé To Develop Immunotherapies For Food Allergies

Nestlé, Enterome Collaboration

Enterome is a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform. As part of the agreement, Enterome will receive €40 million upfront in cash and equity from Nestlé Health Science. It will also be eligible to receive clinical and sales milestone payments for each licensed therapeutic candidate plus royalties on net sales. Enterome will be responsible for leading drug discovery activities and bear related costs up to the investigational new drug (IND) application.

European Supermarket Magazine